Powered By
| The Kogenate FS brand name has been discontinued in the U.S. for reasons unrelated to safety or efficacy. Other brand names or generic alternatives may be available. If you’re currently taking this medication, talk to your healthcare provider about safe options for transitioning to a different treatment. |
Overview
Kogenate FS was approved by the U.S. Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with factor VIII deficiency due to hemophilia A. Kogenate FS was used for perioperative (before, during, and after surgery) care and for routine prophylaxis. Kogenate FS also helped reduce the risk of joint damage in children who had not developed joint damage. The technical name of Kogenate FS was antihemophilic factor (recombinant).
Kogenate FS was a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.
How was it given?
Kogenate FS was given as an intravenous injection. Kogenate FS came as a powder that was reconstituted before injection.
Side effects
The FDA-approved label for Kogenate FS listed common side effects including rash, itching, hives, inflammation or discoloration at the injection site, central venous access device infections, and the development of inhibitors.
Rare but serious side effects listed for Kogenate FS included life-threatening hypersensitivity reactions.
For more information about this treatment, visit:
Become a member to get even more
Join
